DRRX
Durect
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DRRX
Durect Corporation
A company that developing pharmaceuticals for chronic pain and central nervous system disorders
10240 Bubb Road, Cupertino, CA 95014
--
Durect Corporation was incorporated in Delaware on February 6, 1998. The Company is a biopharmaceutical company and its R&D programs are broadly divided into two categories: (i) new chemical entities derived from the Company's epigenetic modulator program, in which the Company attempts to discover and develop molecules that have not previously been approved and marketed as therapeutic agents, and (ii) drug delivery programs, in which the Company's formulation expertise and technology are primarily applied to active pharmaceutical ingredients whose safety and efficacy have been previously identified but are intended to be improved in some way through new formulations. The company also manufactures and sells osmotic pumps for laboratory research and design, and develops and manufactures a wide range of standard and custom degradable polymers and excipients for pharmaceutical and medical device customers as raw materials in products.
Company Financials
EPS
DRRX has released its 2024 Q4 earnings. EPS was reported at 0.24, versus the expected -0.16, beating expectations. The chart below visualizes how DRRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DRRX has released its 2024 Q4 earnings report, with revenue of -3.89M, reflecting a YoY change of -18.39%, and net profit of 7.30M, showing a YoY change of 606.87%. The Sankey diagram below clearly presents DRRX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
